Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study

BACKGROUND: LATITUDE was a randomized, double-blind, international and phase 3 study of abiraterone acetate plus prednisone in patients with high-risk metastatic hormone-naïve prostate cancer. In the first interim analysis of LATITUDE (clinical cutoff date: 31 October 2016), significant prolongation...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Hiroyoshi, Shin, Toshitaka, Fukasawa, Satoshi, Hashine, Katsuyoshi, Kitani, Sumiko, Ohtake, Noriyuki, Shibayama, Kazuhiro, Tran, Namphuong, Mundle, Suneel, Fizazi, Karim, Matsubara, Nobuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345218/
https://www.ncbi.nlm.nih.gov/pubmed/32188988
http://dx.doi.org/10.1093/jjco/hyaa030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345218/
https://www.ncbi.nlm.nih.gov/pubmed/32188988
http://dx.doi.org/10.1093/jjco/hyaa030

Ejemplares similares